Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Feb;62(2):156–162. doi: 10.1136/jnnp.62.2.156

Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

N Sommer 1, B Sigg 1, A Melms 1, M Weller 1, K Schepelmann 1, V Herzau 1, J Dichgans 1
PMCID: PMC486727  PMID: 9048716

Abstract

OBJECTIVE: Ocular myasthenia gravis is a subtype of myasthenia gravis that causes relatively mild disability, but may convert into severe generalised muscle weakness. A universal management plan for ocular myasthenia gravis has not been established. This study was performed to determine the outcome of ocular myasthenia gravis with the currently available therapeutic options. METHODS: Retrospective analysis of 78 patients with ocular myasthenia gravis with a mean disease duration of 8.3 (range 0.5-58.3) years. RESULTS: In 54 patients (69%) symptoms and signs remained confined to the extraocular muscles during the observation period. The remaining 24 patients (31%) developed symptoms of generalised myasthenia gravis; 50% of them within two years, 75% within four years after onset. A somewhat reduced risk of generalisation was found in those with mild symptoms, normal repetitive nerve stimulation test, and low or absent antiacetylcholine receptor (AChR) antibodies at the time of diagnosis. Patients receiving immunosuppressive treatment (corticosteroids and/or azathioprine) rarely developed generalised myasthenia gravis (six of 50, 12%). Those without such treatment, usually due to uncertain diagnosis and late referral, converted into generalised myasthenia gravis significantly more often (18 of 28, 64%). CONCLUSIONS: The prognosis of ocular myasthenia gravis is good. A conventional scheme with short-term corticosteroids and long-term azathioprine seems adequate to achieve remission in most patients. The proportion of patients developing generalised myasthenia gravis was smaller in this population compared with previously published groups (usually 50%-70%). Early immunosuppressive treatment is at least partially responsible for this finding. Thymectomy (performed here in 12 patients with an abnormal chest CT) also correlated with a good outcome, but had no apparent advantage over medical treatment alone.

Full text

PDF
156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergoffen J., Zmijewski C. M., Fischbeck K. H. Familial autoimmune myasthenia gravis. Neurology. 1994 Mar;44(3 Pt 1):551–554. doi: 10.1212/wnl.44.3_part_1.551. [DOI] [PubMed] [Google Scholar]
  2. Bever C. T., Jr, Aquino A. V., Penn A. S., Lovelace R. E., Rowland L. P. Prognosis of ocular myasthenia. Ann Neurol. 1983 Nov;14(5):516–519. doi: 10.1002/ana.410140504. [DOI] [PubMed] [Google Scholar]
  3. Christensen P. B., Jensen T. S., Tsiropoulos I., Sørensen T., Kjaer M., Højer-Pedersen E., Rasmussen M. J., Lehfeldt E. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand. 1995 Mar;91(3):192–195. doi: 10.1111/j.1600-0404.1995.tb00432.x. [DOI] [PubMed] [Google Scholar]
  4. Compston D. A., Vincent A., Newsom-Davis J., Batchelor J. R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980 Sep;103(3):579–601. doi: 10.1093/brain/103.3.579. [DOI] [PubMed] [Google Scholar]
  5. Cornelio F., Peluchetti D., Mantegazza R., Sghirlanzoni A., Collarile C. The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis. Ann N Y Acad Sci. 1987;505:517–525. doi: 10.1111/j.1749-6632.1987.tb51320.x. [DOI] [PubMed] [Google Scholar]
  6. Daroff R. B. The office Tensilon test for ocular myasthenia gravis. Arch Neurol. 1986 Aug;43(8):843–844. doi: 10.1001/archneur.1986.00520080081029. [DOI] [PubMed] [Google Scholar]
  7. Drachman D. B. Myasthenia gravis. N Engl J Med. 1994 Jun 23;330(25):1797–1810. doi: 10.1056/NEJM199406233302507. [DOI] [PubMed] [Google Scholar]
  8. Evoli A., Tonali P., Bartoccioni E., Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988 Jan;77(1):31–35. doi: 10.1111/j.1600-0404.1988.tb06970.x. [DOI] [PubMed] [Google Scholar]
  9. Genkins G., Sivak M., Tartter P. I. Treatment strategies in myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21;681:603–608. doi: 10.1111/j.1749-6632.1993.tb22952.x. [DOI] [PubMed] [Google Scholar]
  10. Grob D., Arsura E. L., Brunner N. G., Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472–499. doi: 10.1111/j.1749-6632.1987.tb51317.x. [DOI] [PubMed] [Google Scholar]
  11. Hohlfeld R., Michels M., Heininger K., Besinger U., Toyka K. V. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988 Feb;38(2):258–261. doi: 10.1212/wnl.38.2.258. [DOI] [PubMed] [Google Scholar]
  12. Johns T. R. Long-term corticosteroid treatment of myasthenia gravis. Ann N Y Acad Sci. 1987;505:568–583. doi: 10.1111/j.1749-6632.1987.tb51325.x. [DOI] [PubMed] [Google Scholar]
  13. Kissel J. T., Levy R. J., Mendell J. R., Griggs R. C. Azathioprine toxicity in neuromuscular disease. Neurology. 1986 Jan;36(1):35–39. doi: 10.1212/wnl.36.1.35. [DOI] [PubMed] [Google Scholar]
  14. Lanska D. J. Indications for thymectomy in myasthenia gravis. Neurology. 1990 Dec;40(12):1828–1829. doi: 10.1212/wnl.40.12.1828. [DOI] [PubMed] [Google Scholar]
  15. Lefvert A. K., Bergström K., Matell G., Osterman P. O., Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978 May;41(5):394–403. doi: 10.1136/jnnp.41.5.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Limburg P. C., The T. H., Hummel-Tappel E., Oosterhuis H. J. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci. 1983 Mar;58(3):357–370. doi: 10.1016/0022-510x(83)90095-3. [DOI] [PubMed] [Google Scholar]
  17. Melms A., Schalke B. C., Kirchner T., Müller-Hermelink H. K., Albert E., Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest. 1988 Mar;81(3):902–908. doi: 10.1172/JCI113401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mertens H. G., Balzereit F., Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol. 1969;2(6):321–339. doi: 10.1159/000113809. [DOI] [PubMed] [Google Scholar]
  19. Miano M. A., Bosley T. M., Heiman-Patterson T. D., Reed J., Sergott R. C., Savino P. J., Schatz N. J. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology. 1991 Jun;41(6):919–921. doi: 10.1212/wnl.41.6.919. [DOI] [PubMed] [Google Scholar]
  20. Moorthy G., Behrens M. M., Drachman D. B., Kirkham T. H., Knox D. L., Miller N. R., Slamovitz T. L., Zinreich S. J. Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians. Neurology. 1989 Sep;39(9):1150–1154. doi: 10.1212/wnl.39.9.1150. [DOI] [PubMed] [Google Scholar]
  21. Newsom-Davis J. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve. 1990 Dec;13(12):1186–1186. [PubMed] [Google Scholar]
  22. Oda K., Goto I., Kuroiwa Y., Onoue K., Ito Y. Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens. Neurology. 1980 May;30(5):543–546. doi: 10.1212/wnl.30.5.543. [DOI] [PubMed] [Google Scholar]
  23. Oosterhuis H. J. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989 Oct;52(10):1121–1127. doi: 10.1136/jnnp.52.10.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pinching A. J., Peters D. K. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976 Dec 25;2(8000):1373–1376. doi: 10.1016/s0140-6736(76)91917-6. [DOI] [PubMed] [Google Scholar]
  25. Rowland L. P. Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):644–659. doi: 10.1136/jnnp.43.7.644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schumm F., Stöhr M. Accessory nerve stimulation in the assessment of myasthenia gravis. Muscle Nerve. 1984 Feb;7(2):147–151. doi: 10.1002/mus.880070211. [DOI] [PubMed] [Google Scholar]
  27. Schumm F., Wiethölter H., Fateh-Moghadam A., Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985 Apr;48(4):332–337. doi: 10.1136/jnnp.48.4.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Seybold M. E. The office Tensilon test for ocular myasthenia gravis. Arch Neurol. 1986 Aug;43(8):842–843. doi: 10.1001/archneur.1986.00520080080028. [DOI] [PubMed] [Google Scholar]
  29. Soliven B. C., Lange D. J., Penn A. S., Younger D., Jaretzki A., 3rd, Lovelace R. E., Rowland L. P. Seronegative myasthenia gravis. Neurology. 1988 Apr;38(4):514–517. doi: 10.1212/wnl.38.4.514. [DOI] [PubMed] [Google Scholar]
  30. Sommer N., Melms A., Weller M., Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol. 1993;84(4):309–333. doi: 10.1007/BF01215447. [DOI] [PubMed] [Google Scholar]
  31. Sommer N., Willcox N., Harcourt G. C., Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol. 1990 Sep;28(3):312–319. doi: 10.1002/ana.410280303. [DOI] [PubMed] [Google Scholar]
  32. Somnier F. E., Keiding N., Paulson O. B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol. 1991 Jul;48(7):733–739. doi: 10.1001/archneur.1991.00530190081019. [DOI] [PubMed] [Google Scholar]
  33. Tindall R. S. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol. 1981 Nov;10(5):437–447. doi: 10.1002/ana.410100506. [DOI] [PubMed] [Google Scholar]
  34. Tindall R. S., Phillips J. T., Rollins J. A., Wells L., Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21;681:539–551. doi: 10.1111/j.1749-6632.1993.tb22937.x. [DOI] [PubMed] [Google Scholar]
  35. Tola M. R., Granieri E., Paolino E., Caniatti L., Quatrale R., Mazzanti B., D'Alessandro R. Epidemiological study of myasthenia gravis in the province of Ferrara, Italy. J Neurol. 1989 Oct;236(7):388–390. doi: 10.1007/BF00314895. [DOI] [PubMed] [Google Scholar]
  36. Toyka K. V., Heininger K. Acetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis. Untersuchung bei 406 gesicherten Fällen. Dtsch Med Wochenschr. 1986 Sep 19;111(38):1435–1439. doi: 10.1055/s-2008-1068647. [DOI] [PubMed] [Google Scholar]
  37. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1246–1252. doi: 10.1136/jnnp.48.12.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Willcox N., Schluep M., Ritter M. A., Newsom-Davis J. The thymus in seronegative myasthenia gravis patients. J Neurol. 1991 Aug;238(5):256–261. doi: 10.1007/BF00319736. [DOI] [PubMed] [Google Scholar]
  39. Willcox N., Schluep M., Ritter M. A., Schuurman H. J., Newsom-Davis J., Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol. 1987 Jun;127(3):447–460. [PMC free article] [PubMed] [Google Scholar]
  40. Witte A. S., Cornblath D. R., Parry G. J., Lisak R. P., Schatz N. J. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984 Jun;15(6):602–605. doi: 10.1002/ana.410150615. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES